Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2 CAR-T (Fuda Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GD2 CAR-T (Fuda Cancer Hospital) is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting the disialoganglioside GD2. Developed by Fuda Cancer Hospital in Guangzhou, China, the therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes GD2, an antigen highly expressed on the surface of glioma cells and other neuroectodermal tumors. This treatment is designed for patients with GD2-positive recurrent or metastatic glioma who have exhausted standard treatment options. Once infused, the CAR-T cells bind to the GD2 antigen, triggering T-cell activation, proliferation, and the subsequent destruction of the tumor cells. Clinical trials are evaluating its safety and efficacy in patients with advanced glioma.
- Other names
- GD2 CAR-T immunotherapyGD-2 CAR-T immunotherapyGD 2 CAR-T immunotherapyGD2-targeted CAR-T cell therapyGD-2-targeted CAR-T cell therapyGD 2-targeted CAR-T cell therapyGD2 CAR-T-Fuda Cancer Hospital, Guangzhou-glioma
02
Targets
GD2
Beyond the preview
Go deeper on GD2 CAR-T (Fuda Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2 CAR-T (Fuda Cancer Hospital).